Background
Phase 3, open-label, multicenter RCT (PIVOTAL). 2,141 hemodialysis patients receiving maintenance iron therapy. Compared a high-dose proactive IV iron strategy (iron sucrose 400 mg/month if ferritin <700 ng/mL and TSAT <40%) versus a low-dose reactive strategy (iron sucrose 0–400 mg/month only if ferritin <200 ng/mL or TSAT <20%). Iron deficiency is ubiquitous in dialysis patients due to ongoing blood losses, reduced absorption, and high erythro- poiesis stimulated by ESA therapy. Prior evidence suggested high ferritin might correlate with harm, but causation was unclear. PIVOTAL tested the safety and efficacy of a more aggressive iron strategy.
Interventions and follow up
Arm A: High-dose proactive IV iron sucrose 400 mg/month (if ferritin <700 ng/mL and TSAT <40%)
Arm B: Low-dose reactive IV iron sucrose (only if ferritin <200 ng/mL or TSAT <20%; up to 400 mg/month)
Primary endpoint: Composite of non-fatal MI, non-fatal stroke, HF hospitalization, or death — non-inferiority for the high-dose strategy
mFollow up: Median 2.1 year
Arm B: Low-dose reactive IV iron sucrose (only if ferritin <200 ng/mL or TSAT <20%; up to 400 mg/month)
Primary endpoint: Composite of non-fatal MI, non-fatal stroke, HF hospitalization, or death — non-inferiority for the high-dose strategy
mFollow up: Median 2.1 year
Results
Primary composite (cardiovascular event or death): 29.3% (high-dose) vs 32.4% (low-dose); HR 0.85, 95% CI 0.73–1.00 — non-inferior and superior (P<.001 non-inferiority; P=.04 superiority)
ESA dose: Significantly lower in high-dose arm (P<.001)
Hemoglobin: Higher in high-dose arm (no significant difference in AEs)
Mean ferritin (high-dose arm): ~500 ng/mL vs ~300 ng/mL (low-dose)
ESA dose: Significantly lower in high-dose arm (P<.001)
Hemoglobin: Higher in high-dose arm (no significant difference in AEs)
Mean ferritin (high-dose arm): ~500 ng/mL vs ~300 ng/mL (low-dose)
Adverse events
Main adverse events: No significant difference in infections, cardiovascular events, or hospitalizations beyond the primary composite. Iron overload (ferritin >700 ng/mL) in ~10% of high-dose arm — managed by dose adjustment. No increase in bacteremia, oxidative stress events, or thrombosis. Liver iron not assessed. The high-dose arm required fewer ESA dose adjustments.
Conclusions
High-dose proactive IV iron in hemodialysis was non-inferior and superior to low-dose reactive dosing for cardiovascular outcomes, while reducing ESA requirements, supporting a liberal IV iron strategy in dialysis patients.
Key Limitations
Key Limitations: Open-label design — iron dose assignment not blinded. Iron sucrose specific — results may not generalize to other IV iron formulations (ferric carboxymaltose, ferumoxytol). Upper ferritin limit of 700 ng/mL prevents evaluation of very high ferritin safety. Non-inferiority design with post-hoc superiority claim requires cautious interpretation. Generalizing to CKD patients not on dialysis is unclear. The benefit may partly reflect ESA reduction rather than direct iron effects.
Clinical Context
PIVOTAL challenged the long-standing conservative approach to iron dosing in dialysis (avoid ferritin >500 ng/mL). It showed that higher iron dosing (targeting ferritin up to 700 ng/mL) was safe and actually better for cardiovascular outcomes. KDIGO 2012 and NICE guidelines had recommended conservative iron targets; PIVOTAL has influenced updated guidelines to allow higher ferritin targets. Oral iron is largely ineffective in dialysis. IV iron formulations differ in pharmacokinetics, but PIVOTAL specifically used iron sucrose.
References